Tonix Pharmaceuticals
Tonix Pharmaceuticals' revenue rose 29.9% to $13 million in fiscal 2025. Its operating margin was −959.0%, up from −1,354.3% a year earlier. Free cash flow was −$103 million. It paid out $14 million in dividends and buybacks. The diluted share count rose 1055.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Tonix Pharmaceuticals lost money in fiscal 2025: a net loss of $124 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 179 | 120 | 25 | 99 | 208 |
| Debt incl. finance leases | — | — | 11 | 9 | — |
| Net debt (negative means net cash) | — | — | −14 | −90 | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | 0.1x | 0.1x | — |
| Interest coverage | — | — | −1,345.2x | −110.8x | −1,412.4x |
| Current ratio | 8.7x | 7.2x | 2.5x | 6.5x | 7.4x |
| Quick ratio | 8.7x | 7.2x | 1.8x | 6.0x | 7.3x |
Cash flow
Projections
Project Tonix Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $458,758 of Tonix Pharmaceuticals shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 27, 2026 | Seth LedermanChief Executive Officer, Director | Bought | 2,000 | $13.79 | $27,580 | Form 4 |
| Aug 20, 2026 | Richard H BaggerDirector | Bought | 1,000 | $12.60 | $12,600 | Form 4 |
| Jun 12, 2026 | Carolyn E. TaylorDirector | Bought | 1,415 | $10.55 | $14,928 | Form 4 |
| Jun 9, 2026 | Seth LedermanChief Executive Officer, Director | Bought | 5,000 | $11.79 | $58,950 | Form 4 |
| Jun 8, 2026 | Richard Newcomb StillwellDirector | Bought | 5,000 | $11.65 | $58,250 | Form 4 |
| Mar 31, 2026 | Seth LedermanChief Executive Officer, Director | Bought | 5,000 | $12.62 | $63,100 | Form 4 |
| Mar 18, 2026 | Seth LedermanChief Executive Officer, Director | Bought | 15,000 | $14.89 | $223,350 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 4 of 9 | — |
| Rule of 40 | — | −574.8% | −757.6% |
| Altman Z'' | −14.34 | −9.93 | −0.37 |
| Accruals ratio | −7.7% | −43.6% | −11.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | Pass | — |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | — | Fail | Pass |
| Revenue rose relative to assets | — | Pass | Pass |
| F-score | — | 4 of 9 | — |
Compare
Put Tonix Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Tonix Pharmaceuticals | FY25 | 29.9% | −959.0% | −787.5% | — | — | — | |
| Evommune | FY25 | 85.7% | −623.6% | −589.8% | — | — | — | Compare |
| Pyxis Oncology | FY25 | −14.2% | −609.2% | −458.3% | — | — | — | Compare |
| Prelude Therapeutics | FY25 | 73.4% | −861.3% | −464.3% | — | — | — | Compare |
| Opus Genetics | FY25 | 29.1% | −271.9% | — | — | — | 3 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | — | — | — | — | 8 | 10 | 13 |
| Revenue growth | — | — | — | — | — | — | — | — | 29.9% | 29.9% |
| Gross profit | — | — | — | — | — | — | — | 3 | 2 | 6 |
| Research and development | 28 | 13 | 18 | 18 | 36 | 69 | 82 | 87 | 40 | 44 |
| Operating income | −39 | −21 | −26 | −29 | −50 | −92 | −112 | −118 | −137 | −126 |
| Net income | −39 | −21 | −26 | −29 | −50 | −92 | −110 | −117 | −130 | −124 |
| Diluted EPS (US$) | −924.60 | −190.14 | −1,559.10 | −115.98 | −3.30 | −48.60 | −20.01 | −14,720.25 | −176.60 | −14.57 |
| Diluted shares (millions) | 0 | 0 | 0 | 0 | 16 | 2 | 6 | 0 | 1 | 8 |
| Cash flow | ||||||||||
| Cash from operations | −37 | −19 | −24 | −27 | −49 | −76 | −98 | −102 | −61 | −100 |
| Capital expenditure | 0 | 0 | 0 | 0 | 9 | 35 | 48 | 8 | 0 | 3 |
| Free cash flow | −37 | −19 | −24 | −27 | −57 | −111 | −146 | −110 | −61 | −103 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 0 | 14 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22 | 0 | 0 |
| Stock-based compensation | 3 | 2 | 2 | 2 | 3 | 8 | 11 | 9 | 5 | 6 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | — | 26 | 25 | 11 | 77 | 179 | 120 | 25 | 99 | 208 |
| Debt incl. finance leases | — | — | — | — | — | — | — | 11 | 9 | — |
| Total assets | 28 | 27 | 26 | 15 | 98 | 241 | 226 | 154 | 163 | 277 |
| Total liabilities | 2 | 2 | 3 | 5 | 10 | 22 | 18 | 49 | 23 | 32 |
| Shareholders' equity | 25 | 25 | 24 | 9 | 88 | 219 | 207 | 106 | 140 | 245 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | 39.0% | 23.1% | 49.3% |
| Operating margin | — | — | — | — | — | — | — | −1,523.9% | −1,354.3% | −959.0% |
| Net margin | — | — | — | — | — | — | — | −1,501.8% | −1,288.2% | −946.2% |
| Free cash flow margin | — | — | — | — | — | — | — | −1,414.8% | −604.8% | −787.5% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — | −574.8% | −757.6% |
| Return on capital | — | — | — | — | — | — | — | — | −153.2% | — |
| Return on equity | −118.4% | −84.5% | −108.1% | −173.0% | −104.0% | −60.2% | −51.8% | −74.6% | −106.1% | −64.5% |
| Return on assets | −104.2% | −77.8% | −98.3% | −140.0% | −89.5% | −54.4% | −47.2% | −61.4% | −82.0% | −56.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |